31 research outputs found
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: A case report
Abstract Background Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensitiveness of this type of neoplasia is available, with only one regimen that showed some activity in a metastatic patient. Case presentation We describe the case of a patient bearing a metastatic colonic adenocarcinoma of the tongue submitted to a first-line chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX regimen). After chemotherapy the patient obtained the complete disappearance of the primitive neoplasia located in the body of the tongue, and a tumor size reduction > 50% of liver and lung metastases. Conclusions This case demonstrated the activity of the combination of oxaliplatin and 5-fluorouracil in this very rare neoplasia. The FOLFOX regimen might be considered either in advanced and especially in the neoadjuvant setting, when the reduction of the primary tumor is highly needed
Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy
Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit
Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions
Cross-species infectivity of H3N8 influenza virus in an experimental infection in swine
Avian influenza A viruses have gained increasing attention due to their ability to cross the species barrier and cause severe disease
in humans and other mammal species as pigs. H3 and particularly H3N8 viruses, are highly adaptive since they are found in
multiple avian and mammal hosts. H3N8 viruses have not been isolated yet from humans; however, a recent report showed that
equine influenza A viruses (IAVs) can be isolated from pigs, although an established infection has not been observed thus far in
this host. To gain insight into the possibility of H3N8 avian IAVs to cross the species barrier into pigs, in vitro experiments and
an experimental infection in pigs with four H3N8 viruses from different origins (equine, canine, avian, and seal) were performed.
As a positive control, an H3N2 swine influenza virus A was used. Although equine and canine viruses hardly replicated
in the respiratory systems of pigs, avian and seal viruses replicated substantially and caused detectable lesions in inoculated pigs
without previous adaptation. Interestingly, antibodies against hemagglutinin could not be detected after infection by hemagglutination
inhibition (HAI) test with avian and seal viruses. This phenomenon was observed not only in pigs but also in mice immunized
with the same virus strains. Our data indicated that H3N8 IAVs from wild aquatic birds have the potential to cross the
species barrier and establish successful infections in pigs that might spread unnoticed using the HAI test as diagnostic tool.We thank Jaime Maldonado and HIPRA (Spain) for the A/Swine/Spain/
54008/2004 (H3N2) strain, Edward J. Dubovi and Cornell University for
the A/Canine/NY/105447/08 (H3N8) IAV strain, T. M. Chambers and the
University of Kentucky for the A/Equine/OH/1/03 (H3N8) IAV strain,
and Hon Ip and the U.S. Geological Survey National Wildlife Health
Center for the A/American black duck/Maine/44411-532/2008 (H3N8)
and the A/Harbor Seal/New Hampshire/179629/2011 (H3N8) IAV
strains. We thank Sergio López, David Solanes, Francisco X. Abad, Jordi
Alberola, Jaume Martorell, and Eduard J. Cunilleras for help in providing
different samples and during the experimental infections, as well as the
personnel in Cat3 laboratories and the animal house. We thank Adolfo
García-Sastre for providing materials and for support as the principal
investigator of the NIAID-funded Center for Research in Influenza Pathogenesis
(HHSN266200700010C).
The research leading to these results received funding from the European
Community’s Seventh Framework Programme (FP7, 2007-2013),
the Research Infrastructures Action under grant FP7-228393 (a NADIR
project), and projects AGL2010-22200-C02-01 and AGL2007-60274 of
the Spanish Ministry of Science and Innovation
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
Aim:
Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensure optimal care, especially in frail groups such as cancer patients (pts). This study investigated the efficacy of SARS-CoV-2 pre-procedure screening and whether COVID-19 influenced timely diagnosis and therapy.
Methods:
Data of oncological procedures of pts with confirmed or suspected cancer diagnosis, treated at Oncology Department or coming from Emergency Department of San Luigi Gonzaga Hospital between June 2020 and March 2021 were retrospectively collected. A nasopharyngeal swab (NPS) was performed in outpatients 24/48 h before procedures. Inpatients were tested by NPS before and after hospitalization.
Results:
Two hundred and twenty-one pts were included in this analysis. Median age was 73 years, males were 58%. Eastern Cooperative Oncology Group (ECOG) Performance Status was 0 or 1 in 88% of pts. The most frequent cancer type was lung cancer (57%). Stages IV were 77%. Two hundred and forty-three scheduled procedures were performed with diagnostic (n: 142; 58%), therapeutic (n: 55; 23%), and palliative (n: 46; 19%) intent. One hundred and four and 139 procedures were performed in out- and in-pts, respectively. Of the 234 NPS performed, 10 (4%) were positive. Two pts were infected during hospitalization, 8 in community. Most of them were asymptomatic, while only 2 had mild symptoms. Eight procedures (3%) were postponed, 1 cancelled, while 2 were performed in positive pts. Median time to resolution of the infection was 17 days (11–36). Median delay in the procedures was 25 days (14–55). Five pts started systemic treatment, after a median time of 37.5 days (13–57).
Conclusions:
SARS-CoV-2 infection led to the postponement of a small, but not negligible percentage of oncological procedures. However, the low infection rate observed suggests that structured screening for COVID-19 is critical for the best management of scheduled procedures during pandemic